Clinical Trial

A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators propose a gene therapy strategy using chemical genetic inhibition to intervene in the abnormal activity of the subthalamic nucleus in Parkinson's disease. The investigators design and construct a highly efficient therapeutic injection STP-001 (first drug), through the efficient adeno-associated virus capsid (AAV), neuronal promoter (hSyn), and chemical genetic effector element (hM4Di), and accurately inject the drug into the bilateral subthalamic nucleus, the core pathological nucleus of Parkinson's disease, through stereotactic technology. Combined with a very low dose of clozapine (the second drug), the abnormal activity of the subthalamic nucleus is precisely intervened to improve the core motor symptoms of Parkinson's disease.
Trial Details
NCT Number NCT07085195
Lead Sponsor Ruijin Hospital
Conditions Parkinson Disease (PD), Gene Therapy, Safety and Efficacy, Clozapine
Enrollment 6 participants
Start Date 2025-08-01
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-25